Method of treating and preventing secondary hyperparathyroidism
AssigneeEirgen Pharma Ltd.
InventorsCharles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
Life of this patent
Estimating the term…
Loading patent…
AssigneeEirgen Pharma Ltd.
InventorsCharles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
Estimating the term…
The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D3, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D3 for 25-hydroxyvitamin D repletion and/or maintenance.
A method of treating hyperparathyroidism secondary to chronic kidney disease by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering a 25-hydroxyvitamin D compound by transdermal delivery.
A method of treating hyperparathyroidism secondary to chronic kidney disease in a patient by administering to the patient a 25-hydroxyvitamin D compound by transdermal delivery, whereby the patient's serum total 25-hydroxyvitamin D level is raised to at least 30 ng/mL and the patient's serum iPTH is lowered.
A method of treating hyperparathyroidism secondary to chronic kidney disease in a patient by administering to the patient 25-hydroxyvitamin D3 by transdermal delivery, whereby the patient's serum total 25-hydroxyvitamin D level is raised to at least 30 ng/mL and the patient's serum iPTH is lowered, and wherein the delivery is by transdermal patch having a concentration of the 25-hydroxyvitamin D3 in a range of 1 μg to 1000 μg.
Dependencies are inferred from the claim text.